证券代码：600298 证券简称：安琪酵母 公告编号：2025-063 号 安琪酵母股份有限公司 关于日常关联交易进展的公告 2025年1月15日，安琪酵母股份有限公司（以下简称公司） 召开第九届董事会第三十九次会议审议通过了《关于2024年度日 常关联交易确认及2025年度日常关联交易预计的议案》。具体内 容详见公司2025年1月16日在《上海证券报》《中国证券报》《证 券时报》及上海证券交易所网站（www.sse.com.cn）上披露的 "2025-004号"公告。 注 2：2024 年 7 月，公司高管覃先武不再担任湖北微琪生物科技有限公司（简称 湖北微琪）董事，故上表所列与湖北微琪发生日常关联交易的预计时间范围为 2025 年 1 月至 7 月。 2025年度日常关联交易预计情况可能与实际情况存在差异， 公司可以根据实际交易情况，在同一控制下的不同关联方之间进 行额度调剂（包括不同关联交易类型间的调剂），总额不超过预 计金额。 截至 2025 年 6 月 30 日，公司及控股子公司与关联方累计发 生的关联交易金额没有超过此前预计的关联交易金额总额。以上 关联交易金额未经审计，须以会计师年度审计确认后的 ...

证券代码：600298 证券简称：安琪酵母 公告编号：2025-062 号 安琪酵母股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | 被担保人名称 | 安琪酵母（宜昌高新区）有限公司 | | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 20,000 万元 | | | | 担保对象 | 实际为其提供的担保余额 | 3,205 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | | □不适用：_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 300,000 万元 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 27.70% | | | □对外担 ...

Investment Rating - The report maintains a cautious outlook on the liquor industry, suggesting a bottoming opportunity for investment in high-end liquor brands and potential cyclical recovery in beer and yellow wine sectors [2][11][12]. Core Insights - The liquor industry is experiencing pressure on sales due to external risks and a need for demand improvement, with expectations for the price of original box Feitian Moutai to stabilize around 2000 RMB [2][11]. - The beer industry is showing signs of stabilization with a recovery in dining demand and potential for high-frequency sales tracking, suggesting a favorable outlook for the upcoming peak season [3][12]. - The yellow wine sector is witnessing a trend towards premiumization and market promotion efforts by leading brands, indicating a shift in consumer preferences [3][13]. - The snack food industry remains robust, driven by channel expansion and new product penetration, with expectations for continued high growth in Q2 [3][12]. - The soft drink sector is seeing demand improvement driven by health-oriented and functional beverages, with a positive outlook for brands like Dongpeng Beverage and Nongfu Spring [4][14]. - The seasoning industry is stabilizing at a low point, with growth relying on structural upgrades and increased demand from the restaurant sector [5][15]. Summary by Sections Liquor Industry - Feitian Moutai's original box price is stable between 1900-1950 RMB, with expectations for a price stabilization around 2000 RMB [2][11]. - The industry is under pressure, but the market's expectations for short-term performance have been adequately priced in, suggesting a potential for recovery [12]. Beer Industry - The beer sector is expected to stabilize with a recovery in dining demand and increased focus on non-drinking channels [3][12]. - The industry is positioned for a favorable performance in the upcoming peak season, with anticipated steady mid-year earnings [3][12]. Yellow Wine Industry - The trend towards premiumization is becoming a consensus among leading brands, with increased marketing efforts and a focus on younger consumers [3][13]. Snack Food Industry - The snack food sector is maintaining high growth due to channel expansion and new product introductions, with Q2 performance expected to continue the positive trend [3][12]. Soft Drink Industry - The soft drink market is improving, driven by health and functional beverages, with brands like Dongpeng Beverage and Nongfu Spring expected to perform well [4][14]. Seasoning Industry - The seasoning sector is stabilizing, with growth dependent on structural upgrades and increased demand from the restaurant industry [5][15].

Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities Synthetic Biology Index, which includes 58 companies across various sectors, has seen a decline of 3.42% recently, underperforming compared to the Shanghai Composite Index and the ChiNext Index [5][17] - The first local regulations for synthetic biology manufacturing were passed in Changde, Hunan, aimed at promoting industry development and addressing issues like talent shortages and approval efficiency [8][10] Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector's stocks have shown poor performance, with a recent decline of 3.42%, ranking 32nd among sectors [17] - The top-performing companies include Jincheng Pharmaceutical (+11%), Xinhai Hengli (+10%), and Dongbao Biological (+7%) [18] 1.2 Company Business Progress - Kexin Pharmaceutical's CAR-T therapy targeting Claudin18.2 has received regulatory acceptance for market application, offering new treatment options for advanced gastric cancer patients [23] - Angel Yeast announced a significant investment of 5.56 billion yuan to expand its biological manufacturing center and enhance its product lines [23] - Internationally, Covestro acquired Swiss film technology company Pontacol to strengthen its specialty materials business [25] 1.3 Industry Financing Tracking - The synthetic biology sector is witnessing accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [31] - Zhejiang Rongrui Technology completed nearly 100 million yuan in Pre-A financing, focusing on green biological manufacturing [31] - Avantium, a Dutch biobased PEF company, secured 10 million euros to alleviate short-term liquidity pressures [31]

Group 1 - Hubei Province's direct financing has maintained a high level of around 800 billion yuan for three consecutive years, with nearly 80% of listed companies achieving profitability [1][2] - As of June 30, 2025, Hubei has 191 listed companies, ranking 10th nationally, with 153 domestic and 38 overseas listings [2][3] - The province has a reserve of 1,355 "gold and silver seed" enterprises to support more quality companies to go public [1][4] Group 2 - In Q1 2025, over 70% of Hubei's listed companies were profitable, with notable companies like Jiuzhoutong, CITIC Special Steel, and Wentai Technology reporting revenues exceeding 10 billion yuan [3] - The top ten companies by revenue in Hubei all exceeded 4 billion yuan, indicating strong performance in the region [3] - Hubei has implemented a comprehensive service system for companies to enter the multi-level capital market, aiming to enhance the quality of enterprises [4] Group 3 - Hubei's capital market reforms have led to 20 new listings and approvals annually from 2021 to 2023, with the province ranking 6th nationally for new listings in 2024 [2] - The province aims to achieve five major goals by 2030, including increasing the total number of listed companies and ensuring coverage across all regions [4]

Core Viewpoint - Angel Yeast (600298.SH) is advancing its biotechnology research and industrialization process with a new investment of approximately 502 million yuan in a biomanufacturing center project, reinforcing its strategic goal of becoming a leading global yeast and biotechnology company [1][2]. Group 1: Investment and Projects - The biomanufacturing center project is estimated to cost 502 million yuan, funded by the company's own resources, and is planned to be located next to the company's headquarters, covering an area of about 23 acres, with completion expected in the second half of 2027 [1]. - In addition to the biomanufacturing center, Angel Yeast announced a 230 million yuan investment in a serum-free cell culture medium core technology project, aimed at enhancing product innovation and market transition [2]. Group 2: Market Position and Financial Performance - Angel Yeast is the second-largest yeast company globally, with a total yeast production capacity exceeding 450,000 tons, holding a 55% market share in China and over 20% globally [1]. - The company has maintained stable revenue growth since surpassing 10 billion yuan in revenue in 2021, with projected revenue of 15.197 billion yuan for 2024. In Q1 2025, the company reported total revenue of 3.794 billion yuan, reflecting an 8.95% year-on-year increase, and a net profit of 370 million yuan, up 16.02% year-on-year [2].

Investment and Expansion - Angel Yeast plans to invest CNY 502 million to establish a biomanufacturing center, which will include a seven-story building with a total area of 27,687.65 square meters and an underground parking area for 297 vehicles [1][3] - The project is expected to enhance Angel Yeast's technological innovation capabilities in biomanufacturing, thereby strengthening its profitability and competitive edge [1][3] - Zhou Liufu, a jewelry company, successfully listed on the Hong Kong Stock Exchange, opening with a more than 10% increase and reaching a market capitalization of over HKD 10.5 billion [5] - Zhou Liufu's online sales are projected to grow at a compound annual growth rate of 46.1% from 2022 to 2024, with online sales expected to account for 40% of total revenue by 2024 [5] Market Position and Strategy - Ying Tong Holdings, the largest perfume brand management company in China, officially listed on the Hong Kong Stock Exchange, marking its strong market position [7] - The company is recognized as the third-largest perfume group in the comprehensive markets of mainland China, Hong Kong, and Macau, indicating its robust capability to enter the stock market [7] - Danone's acquisition of The Akkermansia Company aims to strengthen its investment in gut health and next-generation biological research, enhancing its core competitiveness in this field [11][13] - Dazzle Fashion Group announced the closure of all offline stores for its men's brand RAZZLE by August 31, 2025, focusing resources on its core mid-to-high-end women's wear business [16] Retail and Brand Development - HotMaxx's new store format, HotMaxx Super Warehouse, has opened in Beijing, featuring seven product zones while maintaining a low-price strategy [10] - Uniqlo plans to open its first store in southern India in Bangalore, marking a significant expansion into the southern market [18] Leadership Changes - The former business general manager of Kraft Heinz in China has joined Mondelēz as the head of the frozen cake team for Greater China, indicating a strategic focus on growth in the frozen baking sector [20] - Alibaba Group has streamlined its partner organization from 26 to 17 members, emphasizing a focus on frontline business leaders [22] - Anna Wintour announced her resignation as editor-in-chief of American Vogue while retaining her role as global editorial director, reflecting changes in the fashion media landscape [25]

Core Viewpoint - The company plans to implement a Biomanufacturing Center construction project with an estimated total investment of 502.25 million yuan to enhance its biotechnology research and industrialization process [1][2]. Project Overview - The project was approved by the company's board of directors with unanimous support during the third meeting of the Strategic and Sustainable Development Committee [1]. - The project requires further approval from the shareholders' meeting after the board's approval [2]. - The project is not classified as a related party transaction or a major asset restructuring [2]. Basic Project Details - The construction area is 27,687.65 square meters, including two underground levels and 297 parking spaces [2]. - The project will involve the acquisition of equipment for strain selection, cell factory construction, intelligent fermentation, separation and purification, and analysis and testing [2]. - The project will utilize existing water and electricity supplies from the company headquarters and will implement an integrated wastewater treatment system [2]. Environmental Protection - The project will adhere to sustainable development principles and comply with national environmental protection regulations [2]. - Wastewater, domestic waste, and construction waste will be handled according to standards, and new systems will be installed following relevant building and fire safety laws [2]. Necessity Analysis - The project aims to integrate resources to accelerate the research and application of new technologies and processes, transitioning the company's biomanufacturing from traditional to intelligent, green, and high-end models [3]. - It aligns with the company's strategic goal of becoming a leading global yeast enterprise and a first-class international biotechnology company [3]. Impact on the Company - The project aligns with the company's 14th Five-Year Plan and is expected to significantly enhance its technological innovation capabilities in biomanufacturing [4]. - It will further strengthen the company's sustainable profitability and overall competitiveness, contributing to stable development without harming the interests of the company and its shareholders [4].

Core Viewpoint - The company Angel Yeast (600298.SH) plans to implement a biomanufacturing center construction project with an estimated total investment of 502.25 million yuan, funded by the company's own resources. This project aims to enhance the company's biomanufacturing technology innovation capabilities and aligns with its strategic goals [1][3]. Project Details - The project will consist of a 7-story above-ground structure and a 2-story underground facility, covering a total building area of approximately 44,115.97 square meters, including 27,687.65 square meters above ground and 16,427.32 square meters underground, with 297 parking spaces [3]. - The site is located on the south side of the company's headquarters R&D complex, occupying about 23 acres [3]. - The construction period is expected to last 24 months, with plans for completion and operational use in the second half of 2027, subject to actual conditions [3]. - The total estimated investment for the project is 502.25 million yuan, with funding sourced from the company's own capital [3]. Company Performance - Angel Yeast is the largest yeast company in Asia and the second largest globally, holding nearly 60% of the domestic market share and close to 20% of the global market share [3]. - From 1998 to 2024, the company's revenue grew from 138 million yuan to 15.2 billion yuan, a 110-fold increase, with consistent year-on-year growth. Net profit increased from 30.78 million yuan to 1.325 billion yuan, a 43-fold increase [3]. - In the first quarter of 2025, the company's revenue reached 3.794 billion yuan, representing a year-on-year growth of 8.95%, while net profit was 370 million yuan, up 16.02% year-on-year [3].